Company / Current Assets
Corvus Pharmaceuticals, Inc. Current Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$54.4M
FY2024
5-year range
$28.0M / $71.3M
FY2020-FY2024
Trend
+94.6%
vs FY2023
Sector context
#211 of 215
Health Care
What the data says
Among 215 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 2% for current assets. Current Assets returned to growth in FY2024 after 2 years of decline, reaching $54M.
Based on SEC 10-K filings.
$54M in FY2024 with a 5-year CAGR of -7.3%.
Improved from $44M to $54M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- -8.6%
- 5-Year CAGR
- -7.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 215This company $54.4M Sector average $2.5B
▼
-97.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -7.3%, indicating a declining trend.
- In FY2024, current assets increased 94.6% year-over-year.
- Ranks #211 out of 215 companies in the Health Care sector.
- Peak current assets was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $54.4M | +94.6% |
| FY2023 | $28.0M | -36.0% |
| FY2022 | $43.7M | -38.8% |
| FY2021 | $71.3M | +57.3% |
| FY2020 | $45.3M | -42.9% |
| FY2019 | $79.3M | -31.4% |
| FY2018 | $115.6M | +26.7% |
| FY2017 | $91.2M | -32.9% |
| FY2016 | $136.0M | +42.2% |
| FY2015 | $95.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026